UroGen Pharma Ltd. (URGN): Total Assets
$200.46M
As of 2025-12-31
$252.59M
As of 2026-06-30
+13.9%
3-year compound annual growth
+10.4%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $200.46M | -29.8% | 2026-03-02, Balance as of period end |
| 2024-12-31 | $285.71M | +60.2% | 2026-03-02, Balance as of period end |
| 2023-12-31 | $178.31M | +31.5% | 2025-03-10, Balance as of period end |
| 2022-12-31 | $135.62M | +13.3% | 2024-03-14, Balance as of period end |
| 2021-12-31 | $119.75M | -1.9% | 2023-03-24, Balance as of period end |
| 2020-12-31 | $122.00M | -39.7% | 2022-03-21, Balance as of period end |
| 2019-12-31 | $202.39M | +95.4% | 2021-03-18, Balance as of period end |
| 2018-12-31 | $103.56M | +37.1% | 2020-03-02, Balance as of period end |
| 2017-12-31 | $75.55M | +227.7% | 2019-02-28, Balance as of period end |
| 2016-12-31 | $23.06M | n/a | 2018-03-15, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | $200.46M | -29.8% |
| Zevra Therapeutics, Inc. (ZVRA) | 2025-12-31 | $284.73M | +59.8% |
| Zymeworks Inc. (ZYME) | 2025-12-31 | $346.53M | -25.2% |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $166.13M | +32.5% |
| Xencor Inc (XNCR) | 2025-12-31 | $875.50M | -8.0% |
| Siga Technologies Inc (SIGA) | 2025-12-31 | $219.47M | -10.2% |
| Lifecore Biomedical, Inc. (LFCR) | 2025-05-25 | $239.34M | -5.8% |
| Cytokinetics Inc (CYTK) | 2025-12-31 | $1.42B | +1.6% |
| Standard Biotools Inc. (LAB) | 2025-12-31 | $567.75M | -7.3% |
Compare URGN, ZVRA, ZYME, GYRE side by side · Screen every company in Pharmaceutical Preparations ↗